Dj1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DJ1 Gene is involved in biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, or stress response mechanisms.
Dysregulation or mutations in this gene/protein contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
DJ1, also known as PARK7, is a multifunctional protein involved in oxidative stress response, mitochondrial homeostasis, and neuroprotection. It was first identified as an oncogene and later as a cause of familial Parkinson's disease.[1]
DJ1 possesses glyoxalase III activity, converting methylglyoxal and reduced glutathione into lactate and glutathione, respectively. This activity helps protect neurons from carbonyl stress and advanced glycation end-products (AGEs). Under oxidative stress, DJ1 translocates to mitochondria and helps maintain mitochondrial complex I activity.[2]
DJ1 mutations cause autosomal recessive early-onset Parkinson's disease, typically with onset before age 40. Patients present with typical parkinsonian features including tremor, bradykinesia, and rigidity. DJ1 deficiency leads to increased vulnerability of dopaminergic neurons to oxidative stress.[3]
See Parkinson's Disease above. DJ1 mutations account for approximately 1-2% of early-onset PD cases.[4]
DJ1 is ubiquitously expressed with high levels in brain:
Expression is upregulated under oxidative stress conditions, consistent with its role in oxidative stress response.[5]
The study of Dj1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Kahle PJ, et al. Mol Neurobiol. 2009;40(2):129-139.
[2] Taira T, et al. Genes Cells. 2004;9(8):831-838.
[3] Hague S, et al. Neurology. 2003;61(7):919-921.
[4] Irrcher I, et al. Hum Mol Genet. 2010;19(10):2051-2067.
[5] Kim RH, et al. Neurotherapeutics. 2013;10(4):691-702.